Toggle Main Menu Toggle Search

Open Access padlockePrints

Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84

Lookup NU author(s): Dr Jolanta Weaver

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Aim: To assess the effect of nateglinide on efficacy [fasting plasma glucose (FPG), postprandial plasma glucose (PPG) plasma glucose and HbA1c], tolerability and safety in patients with type 2 diabetes mellitus (T2DM) on diet alone or on metformin in subjects up to an age of 84. Methods: In an open-labelled 12-week, parallel study of 358 patients, aged 35-84 years with T2DM, nateglinide was given as either monotherapy in patients previously on diet alone or low-dose sulfonylureas, which required washout before the study (group 1), or as an addition therapy in patients on steady dose of metformin (group 2). Nateglinide 120 mg was given before main meals. HbA1c, FPG and PPG values were taken at the time of breakfast at the beginning and the end of the study. Results: HbA1c fell by a mean of 0.83%, 95% confidence interval (CI) (-0.97, -0.69) (p < 0.001) in group 1, and 0.67%, 95% Cl (-0.77, -0.58) (p < 0.001) in group 2. There was a significant improvement in PPG in group I by a mean reduction of -3.47 mmol/l, 95% Cl (-4.08, -2.87) (p < 0.0001) and in group 2 of -2.41 mmol/l, 95% Cl (-2.84, -1.99) (p < 0.0001). There was an improvement in FPG of -1.2 mmol/l, 95% CI (-1.49, -0.81) (p < 0.0001) and -0.8 mmol/l, 95% CI -(1.07, -0.53) (p < 0.0001) in group 1 and 2 respectively. 44% of patients in group 1 and 34% in group 2 achieved target of HbA1c <7.0 and 66% in group 1 and 59% in group 2 achieved of HbA1c <7.5%. Only one subject on nateglinide and metformin was withdrawn due to the side effect of hypoglycaemia. No patient required third-party assistance nor was admitted to hospital due to hypoglycaemia. Conclusion: These data demonstrate that nateglinide is a safe and effective agent in treatment to target in patients with T2DM up to an age of 84 years.


Publication metadata

Author(s): Weaver JU, Robertson D, Atkin SL, on behalf of The Nateglinide Glycaemic Control Investigators

Publication type: Article

Publication status: Published

Journal: Diabetes Obesity & Metabolism

Year: 2004

Volume: 6

Issue: 5

Pages: 344-352

ISSN (print): 1462-8902

ISSN (electronic): 1463-1326

Publisher: Wiley-Blackwell

URL: http://dx.doi.org/10.1111/j.1462-8902.2004.00353.x

DOI: 10.1111/j.1462-8902.2004.00353.x


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share